BioCentury
ARTICLE | Company News

MRC Technology, DRI Capital deal

July 25, 2016 7:00 AM UTC

MRC Technology sold a portion of its royalty rights to Keytruda pembrolizumab to DRI Capital for $150 million. The not-for-profit said it sold a “percentage of future royalties until a pre-agreed agg...